Literature DB >> 26443620

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

Vaishali Sanchorawala1, Fangui Sun2, Karen Quillen1, J Mark Sloan1, John L Berk3, David C Seldin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26443620     DOI： 10.1182/blood-2015-08-662726

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  26 in total

1.  Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.

Authors:  S Hong; J Valent; L Rybicki; D Abounader; B Bolwell; R Dean; A T Gerds; D Jagadeesh; B K Hamilton; B Hill; M E Kalaycio; B Pohlman; F Reu; C Samaras; R Sobecks; N S Majhail; H D Liu
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 2.  Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.

Authors:  Vaishali Sanchorawala
Journal:  Blood Adv       Date:  2019-01-22

3.  Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.

Authors:  Heather Landau; Oscar Lahoud; Sean Devlin; Nikoletta Lendvai; David J Chung; Ahmet Dogan; C Ola Landgren; Sergio Giralt; Hani Hassoun
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-22       Impact factor: 5.742

Review 4.  Systemic amyloidosis: moving into the spotlight.

Authors:  Oliver C Cohen; Ashutosh D Wechalekar
Journal:  Leukemia       Date:  2020-04-09       Impact factor: 11.528

5.  Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.

Authors:  Marco Basset; Paolo Milani; Mario Nuvolone; Francesca Benigna; Lara Rodigari; Andrea Foli; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood Adv       Date:  2020-09-08

Review 6.  AL amyloidosis: from molecular mechanisms to targeted therapies.

Authors:  Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 7.  Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.

Authors:  Gustavo F Westin; Ajoy L Dias; Ronald S Go
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

8.  Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Francis K Buadi; David Dingli; Suzanne R Hayman; Shaji K Kumar; Nelson Leung; John Lust; S Vincent Rajkumar; Stephen J Russell; Vera J Suman; Jennifer G Le-Rademacher; William J Hogan
Journal:  Cancer       Date:  2016-05-03       Impact factor: 6.860

Review 9.  Small Bowel Amyloidosis.

Authors:  Raghav Bansal; Umer Syed; Jacob Walfish; Joshua Aron; Aaron Walfish
Journal:  Curr Gastroenterol Rep       Date:  2018-03-26

10.  Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.

Authors:  Vaishali Sanchorawala; Shayna Sarosiek; Amanda Schulman; Meredith Mistark; Mary Ellen Migre; Ramon Cruz; J Mark Sloan; Dina Brauneis; Anthony C Shelton
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.